Internal and Emergency Medicine

, Volume 13, Issue 5, pp 699–707 | Cite as

Nuclear factor kappa B in patients with a history of unstable angina: case re-opened

  • Chiara MozziniEmail author
  • Ulisse Garbin
  • Chiara Stranieri
  • Giulia Salandini
  • Giancarlo Pesce
  • Anna Maria Fratta Pasini
  • Luciano Cominacini


This study aims at assessing NF-kB activity in unstable angina (UA) patients free of symptoms after a 1 year follow-up (1YFU). Plasma oxidized low-density lipoproteins (oxLDL), circulating NF-kB, Interleukin 6 (IL-6) and Interleukin 1β (IL-1β), high-sensitivity C-reactive protein (hs-CRP), as markers of oxidative stress and inflammation and plasma double-stranded DNA (ds-DNA), as marker of Neutrophil Extracellular Traps (NETs), were measured in 23 of the previously enrolled 27 UA patients. These measurements were compared to the UA data at baseline, and then compared to the data derived from the stable angina (SA) and controls (C) enrolled in our previous study (we demonstrated that UA had higher levels of NF-kB compared to SA and C). After a 1YFU, UA patients show a significant decrease in NF-kB, IL-6, hs-CRP, oxLDL, and ds-DNA plasma levels (p < 0.001) and in IL-1β and White Blood Cells (WBC) (p < 0.005), without differences in lipid and glucose assessment. If compared to SA and C, UA after a 1YFU have higher levels of NF-kB, IL-6, ds-DNA, WBC, and oxLDL compared to C (p < 0.001), but only IL-6 is higher than SA (p < 0.001). No differences are found in lipid and glucose assessment. After a 1YFU, patients with a history of UA improve their oxidative and inflammatory status, such as the levels of circulating ds-DNA, without achieving the status of C. They become comparable to SA subjects. This study provides new insight on the multiple and apparently contradictory facets of NF-kB in UA and on its possible role as mediator in NETs’ formation.


Unstable and stable angina Nuclear factor kappa B Inflammation Double-stranded DNA NETosis 


Author contributions

CM and LC conceived the study; GP statistically analyzed the data; AF and UG revised the data and the manuscript; GS and CS performed the experiments; CM wrote the manuscript.

Compliance with ethical standards

Conflict of interest

The Authors declare that they have no conflict of interest.

Statement of human and animal rights

The study was conducted in accordance with the ethical standards laid down in the Helsinki Declaration of 1975 and its late amendments.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Mathers CD, Loncar D (2006) Projection of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:2011–2030. CrossRefGoogle Scholar
  2. 2.
    Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 37:267–315. CrossRefGoogle Scholar
  3. 3.
    Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, Huber K, Plebani M, Biasucci LM, Tubaro M, Collinson P, Venge P, Hasin Y, Galvani M, Koenig W, Hamm C, Alpert JS, Katus H, Jaffe AS (2012) How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 33:2252–2257. CrossRefPubMedGoogle Scholar
  4. 4.
    Braunwald E, Morrow DA (2013) Unstable angina: is it time for a requiem? Circulation 127:2452–2457. CrossRefPubMedGoogle Scholar
  5. 5.
    Mockel M, Searle J, Hamm C, Slagman A, Blankenberg S, Huber K, Katus H, Liebetrau C, Muller C, Muller R, Peitsmeyer P, von Recum J, Tajsic M, Vollert JO, Giannitsis E (2015) Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 36:369–376. CrossRefPubMedGoogle Scholar
  6. 6.
    Kumar A, Takada Y, Borick AM, Aggarwal BB (2004) Nuclear factor kappa B: its role in health and disease. J Mol Med 82:434–448. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mitchell S, Vargas J, Hoffmann A (2016) Signaling via the NF-kB system. Syst Biol Med 8:227–241. CrossRefGoogle Scholar
  8. 8.
    Hayden MS, Ghosh S (2008) Shared principles in NF-kappa B signaling. Cell 132:344–362. CrossRefGoogle Scholar
  9. 9.
    Gordon JW, Shaw JA, Kirshenbaum LA (2011) Multiple facets of NF-kB in the heart: to be or not to NF-kB. Circ Res 108:1122–1132. CrossRefPubMedGoogle Scholar
  10. 10.
    Karin M, Lin A (2002) NF-kB at the crossroads of life and death. Nat Immun 3:221–227. CrossRefGoogle Scholar
  11. 11.
    Suzuki N, Kamataki A, Yamaki J, Homma Y (2008) Characterization of circulating DNA in healthy human plasma. Clin Chim Acta 387:55–59. CrossRefPubMedGoogle Scholar
  12. 12.
    Swarup V, Rajeswari A (2007) Circulating (cell-free) nucleic acids—a promising non-invasive tool for early detection of several human diseases. FEBS Lett 581:795–799. CrossRefPubMedGoogle Scholar
  13. 13.
    Cui M, Fan M, Jing R, Wang H, Qin J, Sheng H, Wang Y, Wu X, Zhang L, Zhu J, Ju S (2013) Cell-free circulating DNA: a new biomarker for the acute coronary syndrome. Cardiology 124(2):76–84. CrossRefPubMedGoogle Scholar
  14. 14.
    Chang CP, Chia RH, Wu TL, Tsao KC, Sun CF, Wu JT (2003) Elevated cell-free serum DNA detected in patients with myocardial infarction. Clin Chim Acta 327(1–2):95–101CrossRefPubMedGoogle Scholar
  15. 15.
    Destouni A, Vrettou C, Antonatos D, Chouliaras G, Traeger-Synodinos J, Patsilinakos S, Kitsiou-Tzeli S, Tsigas D, Kanavakis E (2009) Cell-free DNA levels in acute myocardial infarction patients during hospitalization. Acta Cardiol 64(1):51–57. CrossRefPubMedGoogle Scholar
  16. 16.
    Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A (2004) Neutrophil extracellular traps kill bacteria. Science 303(5663):1532–1535. CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch Y, Brinkmann V, Zychlinsky A (2007) Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 176(2):231–241. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Marcos V, Zhou Z, Yildirim AO, Bohla A, Hector A, Vitkov L, Wiedenbauer E-M, Krautgartner WD, Stoiber W, Belohradsky BH (2010) CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation. Nat Med 16:1018–1023. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sangaletti S, Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P, Piconese S, Parenza M, Guiducci C, Vitali C (2012) Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood 120:3007–3018. CrossRefPubMedGoogle Scholar
  20. 20.
    Brinkmann V, Zychlinsky A (2012) Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol 198:773–783. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, Scadden DT, Wagner DD (2012) Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA 109:13076–13081. CrossRefPubMedGoogle Scholar
  22. 22.
    Demers M, Wagner DD (2014) NETosis: a new factor in tumour progression and cancer-associated thrombosis. Semin Thromb Haemost 40(3):277–283. CrossRefGoogle Scholar
  23. 23.
    Borissoff JI, Joosen IA, Versteylen MO, Brill A, Fuchs TA, Savchenko AS, Gallant M, Martinod K, Ten Cate H, Hofstra L, Crijns HJ, Wagner DD, Kietselaer BL (2013) Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol 33(8):2032–2040. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Megens RT, Vijayan S, Lievens D, Döring Y, van Zandvoort MA, Grommes J, Weber C, Soehnlein O (2012) Presence of luminal neutrophil extracellular traps in atherosclerosis. Thromb Haemost 107(3):597–598. CrossRefPubMedGoogle Scholar
  25. 25.
    De Boer OJ, Li X, Teeling P, Mackaay C, Ploegmakers HJ, van der Loos CM, Daemen MJ, de Winter RJ, van der Wal AC (2013) Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost 109(2):290–297. CrossRefPubMedGoogle Scholar
  26. 26.
    Mangold A, Alias S, Scherz T, Hofbauer T, Jakowitsch J, Panzenböck A, Simon D, Laimer D, Bangert C, Kammerlander A, Mascherbauer J, Winter MP, Distelmaier K, Adlbrecht C, Preissner KT, Lang IM (2015) Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size. Circ Res 116(7):1182–1192. CrossRefPubMedGoogle Scholar
  27. 27.
    Mozzini C, Garbin U, Fratta Pasini AM, Cominacini L (2016) An exploratory look at NETosis in atherosclerosis. Intern Emerg Med. CrossRefPubMedGoogle Scholar
  28. 28.
    Cominacini L, Anselmi M, Garbin U, Fratta Pasini A, Stranieri C, Fusaro M, Nava C, Agostoni P, Keta D, Zardini P, Sawamura T, Lo Cascio V (2005) Enhanced plasma levels of oxidized low-density lipoprotein increase circulating nuclear factor-kappa B activation in patients with unstable angina. J Am Coll Cardiol 46:799–806. CrossRefPubMedGoogle Scholar
  29. 29.
    Fratta Pasini AM, Anselmi M, Garbin U, Franchi E, Stranieri C, Nava MC, Boccioletti V, Vassanelli L, Cominacini L (2007) Enhanced levels of oxidized low density lipoprotein prime monocytes to cytokine overproduction via upregulation of CD14 and Toll-like receptor 4 in unstable angina. Arterioscler Thromb Vasc Biol 27:1991–1997. CrossRefPubMedGoogle Scholar
  30. 30.
    Lindorfer MA, Schuman TA, Craig ML, Martin EN, Taylor RP (2001) A bispecific dsDNA monoclonal antibody construct for clearance of anti-dsDNA IgG in systemic lupus erythematosus. J Immunol Methods 248(1–2):125–138CrossRefPubMedGoogle Scholar
  31. 31.
    Li Y, Ha T, Gao X, Kelley J, Williams DI, Browder IW, Kao RI, Li C (2004) NF-kB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol 287:H1712–H1721. CrossRefGoogle Scholar
  32. 32.
    Frantz S, Hu K, Bayer B, Gerondakis S, Strottmann J, Adamek A, Ertl G, Bauersachs J (2006) Absence of NF-kB subunit p50 improves heart failure after myocardial infarction. FASEB J 20:1918–1920. CrossRefPubMedGoogle Scholar
  33. 33.
    Dhingra R, Shaw JA, Aviv Y, Kirshenbaum LA (2010) Dichotomous actions of NF-kappaB signaling pathways in heart. J Cardiovasc Transl Res 4:344–354. CrossRefGoogle Scholar
  34. 34.
    You M, Ku PT, Hrdlikova R, Bose HR (1997) Ch-IAP-1 member of the inhibitor of apoptosis protein family is a mediator of the antiapoptotic activity of the v-Rel oncoprotection. Mol Cell Biol 17:7328–7341CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Chu ZL, Mc Kinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW (1997) Suppression of tumour necrosis factor induced death by inhibitor of apoptosis c-IAP2 is under NF-kB control. Proc Natl Acad Sci 94:10057–10062CrossRefPubMedGoogle Scholar
  36. 36.
    Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS (1998) NF-kB antiapoptosis: induction of TRAF1 and TRAF2 and cIAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680–1683CrossRefGoogle Scholar
  37. 37.
    Papa S, Bubici C, Zazzeroni F, Pham CG, Kuntzen C, Knabb JR, Dean K, Franzoso G (2006) The NF- kB- mediated control of JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ 13:712–729. CrossRefPubMedGoogle Scholar
  38. 38.
    Beere HM (2004) The stress of dying: the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 117:2641–2651. CrossRefPubMedGoogle Scholar
  39. 39.
    Beere HM (2005) Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Investig 115:2633–2639. CrossRefPubMedGoogle Scholar
  40. 40.
    Valen G, Hansson GK, Dumitrescu A, Vaage J (2000) Unstable angina activates myocardial heat shock protein 72, endothelial nitric oxide synthase and transcription factor NF kappa B and AP-1. Cardiovasc Res 47:49–56CrossRefPubMedGoogle Scholar
  41. 41.
    Czibik G, Wu Z, Berne G, Tarkka M, Vaage J, Laurikka J, Jarvinen O, Valen G (2008) Human adaptation to ischemia by preconditioning or unstable angina: involvement of nuclear factor kappa B, but not hypoxia-inducible factor 1 alpha in the heart. Eur J Cardiothorac Surg 34:976–984. CrossRefPubMedGoogle Scholar
  42. 42.
    Tahepold P, Vaage J, Starkopt J, Valen G (2003) Hyperoxia elicits myocardial protection through a nuclear factor kappa B-dependent mechanism in the rat heart. J Thorac Cardiovasc Surg 125:650–660. CrossRefPubMedGoogle Scholar
  43. 43.
    Xuan YT, Tang XL, Banerjee S, Takano H, Li RC, Han H, Qlu Y, Li JJ, Bolli R (1999) Nuclear factor kappa B plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res 84:1095–1109CrossRefPubMedGoogle Scholar
  44. 44.
    Misra A, Haudek SB, Knuefermann P, Vallejo JG, Chen ZJ, Michael LH, Sivasubramanian N, Olson EN, Entman ML, Mann DI (2003) Nuclear factor kappa B protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction. Circulation 108:3075–3078. CrossRefPubMedGoogle Scholar
  45. 45.
    Libby P (2013) Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 368:2004–2013. CrossRefPubMedGoogle Scholar
  46. 46.
    Buffon A, Basucci LM, Liuzzo G (2002) Widespread coronary inflammation in unstable angina. N Engl J Med 347:5–12. CrossRefPubMedGoogle Scholar
  47. 47.
    Bogaty P, Boyer L, Simard S, Dauwe F, Dupuis R, Verret B, Huynh T, Betrand F, Dagenais GR, Brophy JM (2008) The RISCA (Recurrence and Inflammation in the Acute Coronary Syndromes) Study. Clinical utility of C-reactive protein measured ad admission, hospital discharge and 1 month later to predict outcome in patients with acute coronary syndrome. J Am Coll Cardiol 51(24):2339–2346. CrossRefPubMedGoogle Scholar
  48. 48.
    Liuzzo G, Biasucci LM, Gallimore JR (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Eng J Med 331:417–424. CrossRefGoogle Scholar
  49. 49.
    Biasucci LM, Liuzzo G, Grillo RL (1999) Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99:855–860CrossRefPubMedGoogle Scholar
  50. 50.
    Liuzzo G, Santamaria M, Biasucci LM, Narducci M, Colafrancesco V, Porto A, Brugaletta S, Pinnelli M, Rizzello V, Maseri A, Crea F (2007) Persistent activation of Nuclear Factor Kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein. J Am Coll Cardiol 49:185–194. CrossRefPubMedGoogle Scholar
  51. 51.
    Lapponi MJ, Carestia A, Landoni VI, Rivadeneyra L, Etulain J, Negrotto S, Pozner RG, Schattner M (2013) Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. J Pharmacol Exp Ther 345(3):430–437. CrossRefPubMedGoogle Scholar
  52. 52.
    Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agent aspirin and salicylate inhibit the activity of IkB kinase beta. Nature 396:77–80. CrossRefPubMedGoogle Scholar
  53. 53.
    Mc Donald PP, Bald A, Cassatella MA (1997) Activation of the NF-kappaB pathway by inflammatory stimuli in human neutrophils. Blood 89:3421–3433Google Scholar
  54. 54.
    Massberg S, Grahl L, von Bruehl ML (2010) Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 16:887–896. CrossRefPubMedGoogle Scholar
  55. 55.
    Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115–126CrossRefGoogle Scholar
  56. 56.
    Ridker PM, Rifai N, Stampfer MJ, Hennekens CH (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101:1767–1772CrossRefPubMedGoogle Scholar
  57. 57.
    Libby P, Ridker PM, Hansson GK (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54:2129–2138. CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A (1996) Elevated levels of Interleukin-6 in unstable angina. Circulation 94:874–877CrossRefPubMedGoogle Scholar
  59. 59.
    Dinarello CA (2000) The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 343:732–734. CrossRefGoogle Scholar
  60. 60.
    Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550. CrossRefGoogle Scholar
  61. 61.
    Sims JE, Smith DE (2010) The IL-1 family: regulators of immunity. Nat Rev Immunol 10:89–102. CrossRefPubMedGoogle Scholar
  62. 62.
    Stutz A, Golenbock DT, Latz E (2009) Inflammasomes: too big to miss. J Clin Invest 119:3502–3511. CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Ogura Y, Sutterwala FS, Flavell RA (2006) The inflammasome: first line of the immune response to cell stress. Cell 126:659–662. CrossRefGoogle Scholar
  64. 64.
    Rajama K, Lappalainen J, Oorni K (2010) Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5:e11765. CrossRefGoogle Scholar
  65. 65.
    Ridker P, Howard C, Walter V, Everett B, Libby P, Hensen J, Thuren T (2012) Effects of interleukin-1 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126:2739–2748. CrossRefPubMedGoogle Scholar
  66. 66.
    Warnatsch A, Ioannou M, Wang Q, Papayannopoulos V (2015) Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 349(6245):316–320. CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Joshi MB, Lad A, Prasad AB, Balakrishnan A, Ramachandra L, Satyamoorthy K (2013) High glucose modulates IL-6 mediated immune homeostasis through impeding neutrophil extracellular trap formation. FEBS Lett 587:2241–2246. CrossRefPubMedGoogle Scholar
  68. 68.
    Ikeda U, Ito T, Shimada K (2001) Interleukin-6 and acute coronary syndrome. Clin Cardiol 24(11):701–704CrossRefGoogle Scholar
  69. 69.
    Rus HG, Vlaicu R, Niculescu F (1996) Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 127(2):263–271CrossRefPubMedGoogle Scholar
  70. 70.
    Manten A, de Winter RJ, Minnema MC, ten Cate H, Lijmer JG, Adams R, Peters RJ, van Deventer SJ (1998) Procoagulant and proinflammatory activity in acute coronary syndromes. Cardiovasc Res 40(2):389–395CrossRefPubMedGoogle Scholar
  71. 71.
    Wang XH, Liu SQ, Wang YL, Jin Y (2014) Correlation of serum high-sensitivity C-reactive protein and interleukin-6 in patients with acute coronary syndrome. Genet Mol Res 13(2):4260–4266CrossRefPubMedGoogle Scholar
  72. 72.
    Lai CL, Ji YR, Liu XH, Xing JP, Zhao JQ (2011) Relationship between coronary atherosclerosis plaque characteristics and high sensitivity C-reactive proteins, interleukin-6. Chin Med J (Eng) 124(16):2452–2456Google Scholar
  73. 73.
    Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M (1995) Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Investig 96(6):2758–2767. CrossRefPubMedGoogle Scholar
  74. 74.
    Neumann FJ, Ott I, Marx N, Luther T, Kenngott S, Gawaz M, Kotzsch M, Schömig A (1997) Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 17(12):3399–3405CrossRefPubMedGoogle Scholar
  75. 75.
    Gwechenberger M, Mendoza LH, Youker KA, Frangogiannis NG, Smith CW, Michael LH, Entman ML (1999) Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 99(4):546–551CrossRefPubMedGoogle Scholar
  76. 76.
    Caselli C, De Graaf MA, Lorenzoni V, Rovai D, Marinelli M, Del Ry S, Giannessi D, Bax JJ, Neglia D, Schlte AJ (2015) HDL cholesterol, leptin and interleukin-6 predict high risk coronary anatomy assessed by CT angiography in patients with stable chest pain. Atherosclerosis 241(1):55–61. CrossRefPubMedGoogle Scholar
  77. 77.
    Koyama K, Yoneyama K, Mitarai T, Ishibashi Y, Takahashi E, Kongoji K, Harada T, Akashi YJ (2015) Association between inflammatory biomarkers and thin-cap fibroatheroma detected by optical coherence tomography in patients with coronary heart disease. Arch Med Sci 11(3):505–512. CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Plutzki J (2001) Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 88(8A):10K–15KCrossRefGoogle Scholar
  79. 79.
    Brasier AR (2010) The nuclear factor-kB—interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 86:211–218. CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Libermann TA, Baltimore D (1990) Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10(5):2327–2334CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Lippi G, Sanchis-Gomar F, Cervellin G (2015) Cell-free DNA for diagnosing myocardial infarction: not ready for prime time. Clin Chem Lab Med 53(12):1895–1901. CrossRefPubMedGoogle Scholar
  82. 82.
    Tonello S, Rizzia M, Migliario M, Rocchetti V, Renò F (2017) Low concentrations of neutrophil extracellular traps induce proliferation in human keratinocytes via NF-kB activation. J Dermatol Sci 88:110–116CrossRefPubMedGoogle Scholar

Copyright information

© SIMI 2018

Authors and Affiliations

  1. 1.Department of Medicine, Section of Internal MedicineUniversity of VeronaVeronaItaly
  2. 2.Department of Diagnostic and Public Health, Unit of Epidemiology and Medical StatisticsUniversity of VeronaVeronaItaly

Personalised recommendations